60. Aplastic anemia Clinical trials / Disease details

Clinical trials : 245 / Drugs : 318 - (DrugBank : 86) / Drug target genes : 44 - Drug target pathways : 166

7 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2200056625	2022-03-01	2022-02-09	Clinical study of aplastic anemia combined with recombinant human thrombopoietin and immunosuppressants in the treatment of severe aplastic anemia aplastic anemia	Clinical study of aplastic anemia combined with recombinant human thrombopoietin and immunosuppressants in the treatment of severe aplastic anemia aplastic anemia	Severe Aplastic Anemia	1:IST+rhTPO+Etrapropa;	Henan Cancer Hospital	NULL	Pending	4	70	Both	1:20;	N/A	China
2	NCT03896971 (ClinicalTrials.gov)	November 15, 2019	21/3/2019	Combination of Thrombopoietin Mimetic and Immunosuppressive Therapy in Aplastic Anaemia	Treatment With Thrombopoietin Mimetic Plus Immunosuppressive Therapy in Egyptian Patients With Aplastic Anaemia	Aplastic Anemia	Drug: Combination of thrombopoietin mimetic and cyclosporin A	Safaa AA Khaled	Assiut University	Completed	16 Years	65 Years	All	66	Phase 4	Egypt
3	ChiCTR1800019669	2019-01-01	2018-11-21	A randomized, open-label, single-center controlled trial for the efficacy and safety of recombinant human thrombopoietin injection in the treatment of severe Aplastic Anemia with thrombocytopenia	A randomized, open-label, single-center controlled trial for the efficacy and safety of recombinant human thrombopoietin injection in the treatment of severe Aplastic Anemia with thrombocytopenia	Aplastic anemia,Thrombocytopenia	Group 1:Add rhTPO, 300U/kg qd after ATG treatment for 8 weeks;Group 2:Add rhTPO, 300U/kg qod after ATG treatment for 8 weeks;	Institute of Hematology, People's Hospital, Peking University	NULL	Pending			Both	Group 1:30;Group 2:30;		China
4	NCT02857530 (ClinicalTrials.gov)	August 2016	26/7/2016	Efficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic Anemia	Efficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic Anemia	Anemia, Aplastic	Drug: rhTPO;Drug: placebo	Tianjin Medical University General Hospital	NULL	Not yet recruiting	6 Years	60 Years	Both	250	Phase 2	China
5	ChiCTR-IPR-14005720	2015-01-01	2014-12-17	A single center, Randomized controlled, opened clinical reserch for evaluating the effectiveness of recombinant human thrombopoietin combined with immunosuppressive therapy in the treatment of newly diagnosed acquired severe aplastic anemia	A single center, Randomized controlled, opened clinical reserch for evaluating the effectiveness of recombinant human thrombopoietin combined with immunosuppressive therapy in the treatment of newly diagnosed acquired severe aplastic anemia	severe aplastic anemia	TPO:rTPO;Ciclosporine:Ciclosporine;	Blood Diseases Hospital, Chinese Academy of Medical Sciences	NULL	Recruiting	18	75	Both	TPO:86;Ciclosporine:86;	I (Phase 1 study)	China
6	NCT01328587 (ClinicalTrials.gov)	April 1, 2011	1/4/2011	Eltrombopag for Moderate Aplastic Anemia	A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Moderate Aplastic Anemia Patients	Moderate Aplastic Anemia;Unilineage Bone Marrow Failure Disorders	Drug: Eltrombopag	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Active, not recruiting	2 Years	100 Years	All	34	Phase 2	United States
7	NCT00922883 (ClinicalTrials.gov)	May 29, 2009	16/6/2009	A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients	A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Aplastic Anemia Patients With Immunosuppressive-Therapy Refractory Thrombocytopenia	Anemia, Aplastic;Anemia, Hypoplastic;Thrombocytopenia	Drug: Eltrombopag	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Completed	12 Years	N/A	All	43	Phase 2	United States